Hyderabad to Witness ‘Global Voices, One Vision’ International Health Dialogue 2026, Hosted by Apollo Hospitals
The 13th edition of the International Health Dialogue (IHD) will be hosted by Apollo Hospitals in Hyderabad on January 30 and 31, 2026. The event will bring together global leaders to discuss patient safety, healthcare innovation, and system-wide transformation. The theme of IHD 2026, “Global Voices. One Vision,” emphasizes the shared commitment to building resilient, patient-centric, and technology-enabled healthcare systems. The two-day program will focus on leadership-driven safety models, human-centered design, digital transformation, and excellence in hospital operations, patient experience, and clinical outcomes.
The event will feature four major conferences: the International Patient Safety Conference, Healthcare Operations & Patient Experience Conference, Transforming Healthcare with IT Conference, and CLINOVATE, which will focus on the future of laboratories and diagnostics in patient safety and clinical decision-making. Global policymakers, including ministers of health from Niger, Papua New Guinea, and the Republic of Congo, will participate in the conference, along with prominent international experts such as Dr. Jonathan Perlin and Dr. Carsten Engel.
The conference will also include innovative features such as Safe-A-Thon, a collaborative challenge to develop practical patient safety solutions, and the launch of THNX, India’s first digital health startup community. THNX will facilitate pitch sessions, funding opportunities, and investor interactions. The event is expected to reinforce India’s growing role as a hub for global healthcare thought leadership and innovation.
According to Dr. Sangita Reddy, Joint Managing Director of Apollo Hospitals Group, the International Health Dialogue has evolved into a dynamic global platform where clinicians, innovators, and policymakers come together to shape the future of healthcare. The Hyderabad edition of IHD 2026 will bring together the power of AI, data, and digital ecosystems with the timeless values of empathy and collaboration to make healthcare more predictive, sustainable, and inclusive. With plenary sessions, innovation showcases, and global networking forums, the event is expected to be a significant gathering of global healthcare leaders.
Sun Pharma receives green light for obesity treatment injection similar to Wegovy.
Sun Pharmaceutical Industries has received approval for a weight loss injection similar to Novo Nordisk’s Wegovy. The new treatment, called “SUN-144”, is a once-weekly injection that helps with weight management in adults with obesity or overweight with at least one weight-related condition. This approval marks a significant milestone for Sun Pharma, as it enters the growing market for anti-obesity treatments.
Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been highly successful in treating obesity, with sales exceeding $1 billion in 2022. SUN-144 is also a GLP-1 receptor agonist, which works by mimicking a natural hormone that helps regulate appetite and food intake. Clinical trials have shown that SUN-144 is effective in reducing body weight and improving glycemic control in patients with type 2 diabetes.
The approval of SUN-144 is expected to increase competition in the anti-obesity market, which is currently dominated by Novo Nordisk’s Wegovy and Saxenda. However, Sun Pharma’s entry into the market may also lead to increased accessibility and affordability of these treatments, which could benefit patients who struggle with obesity and related health conditions.
Sun Pharma’s SUN-144 has shown promising results in clinical trials, with significant weight loss and improvements in cardiovascular risk factors. The treatment has also been well-tolerated, with common side effects including nausea, vomiting, and diarrhea. As the global prevalence of obesity continues to rise, the demand for effective and safe treatments is increasing. Sun Pharma’s entry into the market is expected to help meet this demand and provide patients with more options for managing their weight and related health conditions.
The approval of SUN-144 is a significant achievement for Sun Pharma, which has been expanding its portfolio of specialty and generic products. The company has a strong presence in the pharmaceutical industry, with a global footprint and a wide range of products. With the launch of SUN-144, Sun Pharma is poised to become a major player in the anti-obesity market, which is expected to continue growing in the coming years. As the company prepares to launch SUN-144, it is likely to focus on educating healthcare professionals and patients about the benefits and risks of the treatment, as well as its potential to improve health outcomes for individuals with obesity and related conditions.
Lupin achieves top ESG rating from CDP for its efforts in addressing climate change and water security.
Lupin, a global pharmaceutical leader, has been recognized for its exceptional sustainability efforts, receiving the highest “A” leadership rating from the Climate Disclosure Project (CDP) for both Climate Change and Water Security. This prestigious recognition solidifies Lupin’s position among the world’s most sustainable and transparent companies. The double “A” rating reflects Lupin’s significant progress in mitigating climate risks, reducing carbon emissions, and ensuring responsible water management across its operations.
Compared to its previous ratings, Lupin has made substantial improvements, upgrading from “A-” in 2024 and “B” and “C” in 2023 for climate and water, respectively. This remarkable achievement demonstrates Lupin’s commitment to sustainability and its proactive initiatives to minimize its environmental impact. Ramesh Swaminathan, Executive Director and Global CFO, expressed pride in earning the double “A” rating, attributing it to the company’s innovative approaches, collaborative efforts, and transparent practices.
Lupin’s sustainability endeavors have also been recognized by S&P Global, which awarded the company an ESG score of 91 in 2025. This achievement places Lupin among an elite group of companies worldwide that have surpassed the 90-point threshold, demonstrating its best-in-class sustainability performance. The CDP’s strict framework has played a significant role in shaping and accelerating Lupin’s climate initiatives, driving ongoing progress and commitment to establishing new sustainability standards.
The recognition from CDP and S&P Global underscores Lupin’s dedication to generating lasting value for its communities and the planet. As a global pharma leader, Lupin is committed to reducing its environmental impact through innovation, collaboration, and transparency, setting a high standard for sustainability in the industry. With its exceptional achievements, Lupin continues to demonstrate its position as a responsible and sustainable business leader, driving positive change and promoting a more environmentally conscious future.
Zydus Lifesciences introduces India’s first biosimilar version of Nivolumab, a global breakthrough.
Zydus Lifesciences, a leading life sciences company, has launched the world’s first biosimilar of nivolumab in India under the brand name Tishtha. This milestone marks a significant expansion of patient access to cutting-edge cancer therapies, particularly in the field of Immuno-Oncology. Tishtha will be available in two dosage strengths, 100 mg and 40 mg, priced at ₹28,950 and ₹13,950, respectively, which is approximately one-fourth of the reference product. This competitive pricing aims to improve treatment affordability and reduce the financial burden of cancer treatment.
The launch of Tishtha reinforces Zydus Lifesciences’ commitment to patient-centric care, with a focus on providing timely access to affordable and advanced cancer care. The company aims to support patients throughout their treatment journey, ensuring consistency, affordability, and reach. The development and manufacturing of Tishtha in India ensures long-term supply reliability, enabling patients to continue therapy without disruption.
The introduction of Tishtha in India significantly broadens access to advanced Immuno-Oncology treatments, making high-quality biosimilar immunotherapies accessible to a wider patient population. This launch is a pivotal step in Zydus Lifesciences’ efforts to make innovative, affordable healthcare solutions available to patients. By providing a reliable and consistent supply of Tishtha, the company aims to reduce clinical risk and financial stress associated with treatment interruptions.
According to Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences, every patient deserves timely access to affordable and advanced cancer care. The company’s commitment to patient access and affordability is reflected in the pricing of Tishtha, which is designed to minimize drug wastage and optimize dosing. With the launch of Tishtha, Zydus Lifesciences continues to play a leading role in advancing patient-centric Immuno-Oncology care in India, providing patients with access to innovative and affordable treatment options.
Sun Pharma Secures Rs 828 Crore Refund as CESTAT Declares Revenue Department’s Demand as Legally Invalid
Sun Pharmaceutical Industries, one of India’s largest pharmaceutical companies, has won a significant excise refund battle. The Customs, Excise, and Service Tax Appellate Tribunal (CESTAT) ruled in favor of Sun Pharma, dismissing a revenue demand of Rs 828 crore (approximately $112 million USD) as “legally unsustainable.” The tribunal’s decision is a major victory for the company, which had been embroiled in a long-standing dispute with the excise authorities.
At the heart of the dispute was the issue of excise duty refund claims filed by Sun Pharma for the period between 2007 and 2012. The company had claimed a refund of excise duty paid on certain products, which were later exempted from excise duty. However, the excise authorities had rejected the claims, citing various grounds, including alleged suppression of facts and misdeclaration of goods.
The CESTAT, however, found that the revenue demand raised by the excise authorities was not sustainable in law. The tribunal observed that the excise authorities had failed to follow the principles of natural justice and had not provided adequate opportunities to Sun Pharma to respond to the allegations. Furthermore, the CESTAT noted that the excise authorities had not demonstrated any suppression of facts or misdeclaration of goods by Sun Pharma.
The ruling is significant not only for Sun Pharma but also for the entire pharmaceutical industry. The decision sets a precedent for other companies that may be facing similar disputes with the excise authorities. It also highlights the importance of following the principles of natural justice and ensuring that companies are given adequate opportunities to respond to allegations.
The Rs 828 crore refund claim is a substantial amount, and the ruling is expected to provide a significant boost to Sun Pharma’s financials. The company can now claim a refund of the excise duty paid, which will help to improve its cash flows and profitability. The decision also demonstrates the effectiveness of the judicial system in resolving disputes between companies and the government.
In conclusion, the CESTAT’s ruling in favor of Sun Pharma is a major victory for the company and a significant development for the pharmaceutical industry. The decision highlights the importance of following the principles of natural justice and ensuring that companies are given adequate opportunities to respond to allegations. With the Rs 828 crore refund claim now cleared, Sun Pharma can focus on its business operations and growth plans, without the burden of a long-standing dispute with the excise authorities.
Lupin Announces Robust Product Pipeline and Key Strategic Objectives – scanx.trade
Lupin, a leading pharmaceutical company, has unveiled its ambitious product pipeline and strategic targets, showcasing its commitment to driving growth and innovation in the industry. The company has outlined a robust pipeline of new products and formulations, aimed at addressing the evolving needs of patients and healthcare providers worldwide.
Key Highlights of the Product Pipeline:
- Innovative Medicines: Lupin is developing a range of innovative medicines, including biosimilars, complex generics, and novel treatments for diseases such as cancer, diabetes, and cardiovascular conditions.
- Global Expansion: The company is expanding its presence in key markets, including the United States, Europe, and Japan, with a focus on building a strong portfolio of products in these regions.
- Digital Health: Lupin is investing in digital health initiatives, including the development of digital therapeutics and telemedicine platforms, to enhance patient engagement and outcomes.
- Sustainability: The company is committed to reducing its environmental footprint and has set targets to minimize waste, reduce energy consumption, and promote sustainable practices across its operations.
Strategic Targets:
- Revenue Growth: Lupin aims to achieve revenue growth of 10-12% CAGR over the next five years, driven by the launch of new products and expansion into new markets.
- Operating Margin: The company targets an operating margin of 20-22% by FY2025, driven by improved operational efficiency and cost optimization.
- Research and Development: Lupin plans to invest 10-12% of its revenue in research and development, focusing on innovative and complex products.
- Sustainability: The company aims to reduce its carbon footprint by 50% by 2025 and achieve zero waste to landfill by 2030.
Growth Drivers:
- Generic Opportunities: Lupin is well-positioned to capitalize on generic opportunities in the United States and other markets, with a strong portfolio of abbreviated new drug applications (ANDAs) and a robust manufacturing infrastructure.
- Innovation: The company’s focus on innovation, including biosimilars and complex generics, is expected to drive growth and differentiation in the market.
- Emerging Markets: Lupin’s presence in emerging markets, such as India and Latin America, provides a platform for growth and expansion.
Overall, Lupin’s ambitious product pipeline and strategic targets demonstrate its commitment to driving growth, innovation, and sustainability in the pharmaceutical industry. With a strong focus on research and development, digital health, and sustainability, the company is well-positioned to achieve its goals and make a positive impact on patients and healthcare providers worldwide.
Hospitals pioneer a greener future in healthcare, driving the shift towards eco-friendly medical practices.
The healthcare sector is facing a paradox in its approach to protecting life. While its primary principle is “primum non nocere” or “first, do no harm,” the sector itself is contributing to the climate crisis, which is having a devastating impact on human health. The global healthcare sector is among the top five carbon emitters in the world, with hospitals consuming large amounts of energy and water, relying on single-use materials, and generating vast quantities of waste. Every medical procedure, including surgeries, has an environmental footprint, with a single bypass surgery estimated to generate emissions equivalent to those produced by a small petrol car traveling 250 kilometers.
Climate change is already making people sicker, exacerbating respiratory conditions, affecting maternal and neonatal health, and disrupting care in vulnerable communities. The healthcare sector is not only treating the victims of climate change but also contributing to the conditions that create them. To break this cycle, healthcare providers must integrate climate responsibility into their work. Apollo Hospitals, for example, launched the Apollo Sustainability Action Plan in 2021, which aimed to reduce the hospital’s environmental impact. The plan included assessing the hospital’s emissions footprint, increasing the use of renewable energy, reducing waste, and implementing energy-saving projects.
The results have been significant, with 28% of the hospital’s energy now coming from renewable sources, and a reduction in scope one and two emissions. The hospital has also implemented sustainable procurement policies and reduced water consumption. These changes are not just cosmetic but fundamental to how healthcare is delivered in the future. A hospital cannot be considered world-class if it is not environmentally responsible, and no health system can claim to serve people if it contributes to the conditions that harm them. The climate crisis is a health emergency, and healthcare providers must take a leadership role in addressing it. By making sustainability a core value, healthcare providers can reduce their environmental impact and improve the health of their patients and the planet. As Dr. Preetha Reddy, Executive Vice Chairperson of Apollo Hospitals, notes, “the work ahead is complex, but the intention is simple: to care deeply, and to do no harm – not only to those we treat, but also to the world they live in.”
Zydus secures tentative USFDA approval for its 100mg and 150mg Olaparib Tablets.
Zydus Lifesciences Limited, an Indian pharmaceutical company, has received tentative approval from the United States Food and Drug Administration (USFDA) for its Olaparib Tablets, 100 mg and 150 mg. This medication is used to treat certain types of ovarian, breast, pancreatic, and prostate cancers in patients with specific genetic mutations, specifically in the BRCA gene or other homologous recombination repair (HRR) genes.
The approval is a significant milestone for Zydus, as Olaparib tablets had annual sales of $1,379.4 million in the United States as of September 2025, according to IQVIA data. The tablets will be manufactured at Zydus Lifesciences Ltd’s Special Economic Zone (SEZ) facility. This approval marks a major achievement for the company, which has now received a total of 426 approvals and has filed 487 Abbreviated New Drug Applications (ANDAs) since it began the filing process in 2003-04.
The tentative approval of Olaparib tablets demonstrates Zydus’ commitment to providing high-quality, affordable medications to patients in the United States and globally. The company’s strong research and development capabilities, combined with its state-of-the-art manufacturing facilities, have enabled it to develop and commercialize complex medications like Olaparib.
With this approval, Zydus is well-positioned to capitalize on the growing demand for cancer treatments in the United States and other markets. The company’s portfolio of oncology products, including Olaparib, is expected to drive growth and revenue in the coming years. As a leading pharmaceutical company in India, Zydus is dedicated to improving access to affordable healthcare solutions for patients worldwide, and this approval is a significant step towards achieving that goal. Overall, the tentative approval of Olaparib tablets is a major achievement for Zydus and reflects the company’s commitment to innovation, quality, and patient care.
Motilal Oswal Reiterates ‘Buy’ Rating on Piramal Pharma Amid Short-Term Challenges; Analyzes Q2 Earnings – NDTV Profit
Motilal Oswal has maintained a “buy” rating on Piramal Pharma despite the company facing near-term headwinds. The brokerage firm reviewed Piramal Pharma’s Q2 results and noted that the company’s performance was impacted by one-time items and supply chain disruptions. However, Motilal Oswal remains positive on the company’s long-term prospects.
Piramal Pharma’s Q2 revenue grew 9% year-on-year to Rs 1,543 crore, driven by a 13% growth in the pharmaceutical segment. However, the company’s EBITDA margin declined 230 basis points to 17.1% due to higher raw material costs and supply chain disruptions. The brokerage firm noted that the company’s performance was also impacted by one-time items, including a Rs 35 crore provision for a regulatory issue.
Despite the near-term headwinds, Motilal Oswal remains positive on Piramal Pharma’s long-term prospects. The brokerage firm noted that the company’s pharmaceutical segment has a strong product portfolio and a significant presence in the global market. Piramal Pharma’s contract manufacturing business also has a strong client base and a robust order book.
Motilal Oswal has maintained a target price of Rs 2,130 on Piramal Pharma, implying a potential upside of 22% from current levels. The brokerage firm believes that the company’s long-term growth prospects are intact, driven by its strong product portfolio, significant presence in the global market, and robust order book.
The Q2 results of Piramal Pharma were also impacted by the company’s investment in its research and development (R&D) capabilities. The company has increased its R&D spend to 12% of sales, which is expected to drive long-term growth. Motilal Oswal noted that Piramal Pharma’s R&D capabilities are a key differentiator and will help the company to drive growth in the long term.
Overall, Motilal Oswal’s “buy” rating on Piramal Pharma is driven by the company’s strong long-term prospects, despite the near-term headwinds. The brokerage firm believes that the company’s pharmaceutical segment has a strong product portfolio and a significant presence in the global market, and its contract manufacturing business has a strong client base and a robust order book. With a target price of Rs 2,130, Motilal Oswal sees a potential upside of 22% from current levels.
Lupin Bioresearch Center receives a flawless report with zero observations from the USFDA following a successful inspection and evaluation.
The Lupin Bioresearch Center, a prominent research facility, has achieved a significant milestone by receiving zero observations from the United States Food and Drug Administration (USFDA) following a successful inspection and assessment. This impressive feat demonstrates the center’s commitment to maintaining the highest standards of quality, safety, and compliance.
The USFDA inspection and assessment are rigorous processes that evaluate a facility’s adherence to current Good Manufacturing Practices (cGMP) and regulatory requirements. The inspection team reviews various aspects of the facility, including its quality systems, manufacturing processes, and laboratory controls. Receiving zero observations indicates that the Lupin Bioresearch Center has met all the necessary requirements and has demonstrated a strong commitment to quality and compliance.
The success of the Lupin Bioresearch Center can be attributed to its robust quality management system, which ensures that all aspects of its operations are aligned with international standards. The center’s team of experienced professionals has worked tirelessly to implement and maintain a culture of quality, safety, and compliance. This achievement is a testament to their dedication and hard work.
The zero-observation status from the USFDA is a significant accomplishment, as it reinforces the center’s reputation as a reliable and trustworthy partner in the biotechnology and pharmaceutical industries. This recognition will likely boost the center’s business prospects, as it demonstrates its ability to meet the stringent requirements of regulatory authorities.
The Lupin Bioresearch Center’s success has far-reaching implications, as it highlights the importance of quality and compliance in the biotechnology and pharmaceutical sectors. The center’s commitment to maintaining high standards will contribute to the development of safe and effective products, ultimately benefiting patients and consumers worldwide.
In conclusion, the Lupin Bioresearch Center’s achievement of zero USFDA observations is a significant milestone that demonstrates its commitment to quality, safety, and compliance. The center’s robust quality management system, experienced team, and dedication to maintaining high standards have earned it a reputation as a reliable and trustworthy partner in the biotechnology and pharmaceutical industries. This achievement will likely have a positive impact on the center’s business prospects and reinforce its position as a leading research facility.
Eli Lilly’s Mounjaro achieves ₹1 billion in monthly sales in India’s pharma market through partnership with Cipla.
Eli Lilly’s diabetes medication, Mounjaro, has achieved unprecedented success in India’s pharmaceutical market, crossing ₹1 billion in monthly sales. This remarkable feat is a result of the company’s strategic partnership with Cipla, a leading Indian pharmaceutical firm. Mounjaro, which is also known as tirzepatide, is a revolutionary treatment for type 2 diabetes, offering improved glycemic control and weight loss benefits.
The partnership between Eli Lilly and Cipla has enabled the widespread distribution of Mounjaro across India, making it accessible to a large patient population. Cipla’s extensive network and expertise in the Indian market have played a crucial role in the medication’s success. The company’s efforts have helped to raise awareness about Mounjaro’s benefits among healthcare professionals and patients, driving demand and contributing to its impressive sales figures.
Mounjaro’s success in India is significant, given the country’s large and growing diabetic population. According to the International Diabetes Federation, India has over 77 million people living with diabetes, and this number is expected to increase to 134 million by 2045. The need for effective and innovative treatments like Mounjaro is therefore critical, and Eli Lilly’s partnership with Cipla has helped to address this need.
The ₹1 billion monthly sales milestone is a testament to the strong demand for Mounjaro in India and the effectiveness of the partnership between Eli Lilly and Cipla. The medication’s success is expected to continue, driven by its clinical benefits, increasing awareness, and the growing burden of diabetes in the country.
The partnership between Eli Lilly and Cipla is also a notable example of how global pharmaceutical companies can successfully collaborate with local partners to expand their presence in emerging markets. By leveraging Cipla’s expertise and network, Eli Lilly has been able to navigate the complex Indian market and achieve remarkable success with Mounjaro.
In conclusion, Mounjaro’s achievement of ₹1 billion in monthly sales in India is a significant milestone, driven by the effective partnership between Eli Lilly and Cipla. The medication’s success highlights the growing demand for innovative treatments in India’s pharmaceutical market and demonstrates the potential for global companies to achieve success in emerging markets through strategic partnerships. As the burden of diabetes continues to grow in India, Mounjaro is likely to play an increasingly important role in addressing this major public health challenge.
Sun Pharma’s US revenue from innovative medicines now exceeds that of its generic offerings.
Sun Pharmaceutical Industries Ltd. has reported a significant shift in its business mix, with innovative medicines outpacing generic drug sales in the United States during the second quarter of fiscal year 2026. The company’s innovative medicines, including Ilumya, Cequa, and Odomzo, drove strong demand and growth. The recent launch of Leqselvi, a newly approved alopecia treatment, has further accelerated this growth. Leqselvi was acquired through Sun Pharma’s $576 million purchase of Concert Pharma and has been well received in the US market.
The company’s global innovative drug revenue reached $333 million in Q2FY26, up 16.4% year-over-year, accounting for 20.2% of total consolidated revenue. For the first half of FY26, innovative drug sales totaled $644 million, growing 16.6% year-over-year. Sun Pharma’s CEO, Richard Ascroft, noted that sales of innovative medicines will continue to rise as the company prepares to launch its cancer immunotherapy, Unloxcyt.
The company’s executive chairman, Dilip Shanghvi, reaffirmed the company’s focus on expanding its R&D pipeline and is awaiting updated FDA labeling approval for Unloxcyt ahead of its planned US launch in the second half of FY26. This shift towards innovative and specialty medicines is expected to strengthen the company’s margins and enhance market differentiation, securing long-term growth in the US and global pharmaceutical markets.
Sun Pharma’s strategic move towards innovative medicines is a significant development, as it positions the company for sustained growth and profitability. The company’s investment in R&D and its pipeline of new products, including Unloxcyt, are expected to drive future growth. With the pharmaceutical industry increasingly shifting towards innovative and specialty medicines, Sun Pharma’s strategy is well-aligned with industry trends. Overall, the company’s Q2FY26 results indicate a positive outlook for its innovative medicines business, and investors will be watching the company’s progress closely in the coming quarters.
Aurobindo Pharma’s consolidated net sales for September 2025 stood at Rs 8,285.70 crore, marking a 6.28% year-over-year increase.
Aurobindo Pharma, a leading pharmaceutical company, has released its consolidated financial results for the quarter ended September 2025. The company’s net sales for the quarter stood at Rs 8,285.70 crore, representing a year-over-year (Y-o-Y) growth of 6.28%. This growth is a testament to the company’s strong performance and its ability to navigate the challenges in the pharmaceutical industry.
The company’s revenue growth was driven by a combination of factors, including an increase in sales of its existing products, new product launches, and a strong performance in its international markets. Aurobindo Pharma’s international business, which accounts for a significant portion of its revenue, continued to perform well, with sales growth driven by increasing demand for its products in key markets such as the United States and Europe.
The company’s profitability also improved during the quarter, with its EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) margin expanding to 18.1% compared to 17.4% in the same quarter last year. This improvement in profitability was driven by a combination of factors, including cost savings, operational efficiencies, and a favorable product mix.
Aurobindo Pharma’s research and development (R&D) expenses for the quarter stood at Rs 444.6 crore, representing a Y-o-Y increase of 14.4%. The company continues to invest in R&D to develop new products and expand its pipeline, which is expected to drive future growth.
The company’s management expressed satisfaction with the quarterly performance, citing the strong growth in sales and profitability. They also highlighted the company’s focus on expanding its product portfolio, improving operational efficiencies, and investing in R&D to drive future growth.
Overall, Aurobindo Pharma’s consolidated financial results for the quarter ended September 2025 demonstrate the company’s ability to deliver strong growth and profitability in a challenging environment. The company’s focus on expanding its product portfolio, improving operational efficiencies, and investing in R&D is expected to drive future growth and position it for long-term success.
Key highlights of the results include:
* Net sales of Rs 8,285.70 crore, up 6.28% Y-o-Y
* EBITDA margin of 18.1%, up from 17.4% in the same quarter last year
* R&D expenses of Rs 444.6 crore, up 14.4% Y-o-Y
* Strong growth in international markets, driven by increasing demand for the company’s products
* Focus on expanding product portfolio, improving operational efficiencies, and investing in R&D to drive future growth.
Mankind Pharma’s consolidated net profit for Q2 stands at Rs 5.12 billion.
Mankind Pharma Limited is a leading pharmaceutical company based in India that specializes in developing, manufacturing, and marketing a wide range of pharmaceutical formulations and consumer healthcare products. The company’s product portfolio is diverse and comprehensive, covering various acute and chronic therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/central nervous system, vitamins, minerals, and nutrients, and respiratory therapies.
Mankind Pharma’s branded product portfolio is extensive and includes well-known brands such as Nurokind, Telmikind, Manforce, Gudcef, Moxikind, Amlokind, and many others. These brands cater to various healthcare needs, including women’s health, fertility, and critical care. The company’s products are designed to provide effective healthcare solutions to patients, and its portfolio is constantly evolving to meet the changing needs of the healthcare industry.
In addition to its pharmaceutical products, Mankind Pharma also has a strong presence in the consumer healthcare segment, offering a range of products that cater to everyday health needs. The company’s subsidiaries, including Lifestar Pharma Private Limited, Magnet Labs Private Limited, and Jaspack Industries Private Limited, contribute to its overall growth and expansion.
With a strong focus on research and development, Mankind Pharma is committed to innovation and quality, ensuring that its products meet the highest standards of safety and efficacy. The company’s manufacturing facilities are equipped with state-of-the-art technology, and its quality control processes are rigorous and stringent.
Overall, Mankind Pharma Limited is a reputable and trusted name in the Indian pharmaceutical industry, known for its high-quality products, innovative approach, and commitment to customer satisfaction. With a strong product portfolio, extensive distribution network, and dedicated team, the company is well-positioned to continue its growth trajectory and make a significant impact in the global healthcare industry. Through its subsidiaries and branded products, Mankind Pharma is dedicated to providing effective healthcare solutions to patients and improving the quality of life for people around the world.
Sun Pharma’s Q2 net profit has increased by 2.5% to ₹3,118 crore, with a 9% year-over-year revenue growth, despite a 4.1% decline in US sales.
Sun Pharmaceutical Industries has announced its Q2 results, showing a 2.5% increase in net profit to ₹3,118 crore. The company’s revenue growth stood at 9% year-over-year (YoY), driven by strong performance in the domestic market and emerging markets. However, US sales declined 4.1% YoY, which had a negative impact on the company’s overall revenue.
The decline in US sales can be attributed to increased competition and pricing pressure in the generic pharmaceutical market. Despite this, the company’s revenue from emerging markets and the domestic market showed significant growth. The company’s formulation business in emerging markets grew by 14% YoY, while the domestic market formulation business grew by 13% YoY.
Sun Pharma’s revenue from the rest of the world (RoW) markets, excluding the US, also showed a growth of 10% YoY. The company’s specialty business, which includes products such as Ilumya and Cequa, also performed well, with revenue growth of 24% YoY.
The company’s research and development (R&D) expenses increased by 15% YoY to ₹543 crore, as the company continues to invest in new product development and clinical trials. The company’s operating margin stood at 24.1%, which is a decline of 140 basis points YoY, due to higher R&D expenses and increased competition in the US market.
Sun Pharma’s management has said that the company is focusing on launching new products and increasing its presence in emerging markets to drive growth. The company is also working on reducing its dependence on the US market and increasing its revenue from specialty products.
Overall, while Sun Pharma’s Q2 results were impacted by the decline in US sales, the company’s strong performance in the domestic market and emerging markets, along with its growing specialty business, are expected to drive growth in the coming quarters. The company’s focus on new product launches and increasing its presence in emerging markets is also expected to help it navigate the challenges in the US market. With a diverse portfolio of products and a strong presence in several markets, Sun Pharma is well-positioned to achieve long-term growth and success.
Biocon Group wraps up #InvisibleYetImportant campaign, promoting breast cancer awareness
The Biocon Group has successfully concluded its public interest campaign, #InvisibleYetImportant, which aimed to raise awareness about breast cancer and the importance of timely detection and regular screening. The campaign, which coincided with Breast Cancer Awareness Month in October, emphasized the need for creating awareness about the often-overlooked early signs of breast cancer. The core message of the campaign was that even the smallest actions can make a significant difference to one’s health and well-being.
The campaign was structured around three key pillars: Inform, Engage, and Act. It commenced with a powerful video that reminded viewers that some signs of breast cancer may remain hidden until it’s too late. A handbook, “Invisible Yet Important: A Handbook for Breast Cancer Awareness,” was also developed to provide insights on early detection, prevention, and care. The handbook was made available for download, and social media channels were used to amplify the campaign, garnering approximately 500,000 video views and 682,000 overall impressions.
To engage employees, Biocon organized a live quiz on breast cancer awareness, which saw participation from employees across various locations. The top 10 winners were rewarded with a fun tea party celebration, which encouraged meaningful conversations around health, wellness, and preventive care. The campaign also featured expert advice from Dr. Akshita Singh, Senior Breast Consultant Surgeon, who addressed common myths and emphasized the importance of early detection and screening.
Under the #PeopleOfBiocon series, Dr. Kunvar Harsh Upveja, an internal Medico-Oncology expert, shared his perspective on the larger mission of access and equity in cancer care. He emphasized that science saves lives, but only if it reaches everyone, underscoring Biocon’s vision of delivering affordable and accessible therapies globally.
The campaign reflects Biocon Group’s commitment to public health advocacy and community well-being. The company’s spokesperson said that the campaign aimed to build a sustained movement encouraging people to stay informed, adopt preventive health practices, and prioritize early detection. The campaign’s success demonstrates the power of awareness and timely action in changing outcomes for patients, and it serves as a reminder that awareness must be ongoing, and even small steps can have a life-changing impact.
Navi Mumbai airport has collaborated with Apollo Hospitals to establish a 24-hour on-site medical facility equipped with ICU ambulances.
Navi Mumbai International Airport (NMIA) has partnered with Apollo Hospitals to establish a 24×7 on-site medical centre at the airport. The medical centre will provide comprehensive medical care to passengers, staff, and visitors at the airport. The partnership aims to ensure that medical emergencies are handled promptly and efficiently, providing a safe and healthy environment for all stakeholders.
The on-site medical centre will be equipped with state-of-the-art medical facilities, including ICU ambulances, to handle medical emergencies. The centre will be staffed by a team of experienced doctors, nurses, and paramedics from Apollo Hospitals, who will provide round-the-clock medical care. The medical centre will also have telemedicine facilities, allowing for remote consultations with specialists from Apollo Hospitals.
The partnership between NMIA and Apollo Hospitals is a significant step towards providing world-class medical facilities at the airport. The medical centre will cater to a wide range of medical needs, from minor ailments to critical emergencies. The presence of ICU ambulances will ensure that patients can be quickly transported to nearby hospitals if required.
The partnership is also expected to enhance the overall passenger experience at NMIA. Passengers will have access to quality medical care, reducing anxiety and stress in case of medical emergencies. The medical centre will also provide pre-travel medical check-ups, vaccinations, and other health services, making it a one-stop-shop for passengers’ medical needs.
The collaboration between NMIA and Apollo Hospitals is a testament to the airport’s commitment to providing a safe and healthy environment for all stakeholders. The partnership is expected to set a new standard for airport medical facilities in India, providing a benchmark for other airports to follow.
In a statement, the CEO of NMIA said, “We are delighted to partner with Apollo Hospitals to provide world-class medical facilities at our airport. The on-site medical centre will ensure that our passengers, staff, and visitors receive prompt and efficient medical care, enhancing their overall experience at the airport.” The partnership is a significant milestone for NMIA, which is expected to become one of the busiest airports in India in the coming years. With the medical centre and ICU ambulances in place, NMIA is well-equipped to handle medical emergencies and provide a safe and healthy environment for all stakeholders.
Glenmark Aquatic Foundation and Leander Paes’ Samanta Sports Academy Join Hands with KIIT and KISS to Boost Sports Development – orissadiary.com
The Leander Paes-Samanta Sports Academy has partnered with the Glenmark Aquatic Foundation to promote sports development at Kalinga Institute of Industrial Technology (KIIT) and Kalinga Institute of Social Sciences (KISS) in Bhubaneswar, Odisha. This collaboration aims to provide world-class training and infrastructure to aspiring athletes, particularly in the disciplines of tennis and swimming.
The partnership will enable the creation of a state-of-the-art tennis academy at KIIT, which will be equipped with modern facilities and coached by experienced professionals. Leander Paes, the Indian tennis legend, will be closely involved in the development of the academy and will provide guidance and mentorship to young tennis players. The academy will offer training programs, workshops, and competitions to identify and nurture talent from across the region.
In addition to tennis, the partnership will also focus on promoting swimming as a sport at KISS. The Glenmark Aquatic Foundation will work with KISS to establish a swimming program, which will provide training and coaching to students. The program will be designed to promote swimming as a sport and provide opportunities for young swimmers to compete at the national and international levels.
The collaboration between the Leander Paes-Samanta Sports Academy and the Glenmark Aquatic Foundation is expected to have a significant impact on the development of sports in Odisha. The partnership will not only provide opportunities for young athletes to develop their skills but also promote a culture of sportsmanship and healthy competition.
Dr. Achyuta Samanta, the founder of KIIT and KISS, expressed his enthusiasm for the partnership, stating that it will provide a platform for young athletes to pursue their passion for sports and achieve excellence. He also acknowledged the importance of sports in promoting education, health, and overall development.
The partnership is also expected to contribute to the growth of sports infrastructure in Odisha, which has been a key focus area for the state government. The collaboration will help to create world-class facilities and provide opportunities for athletes to train and compete at the highest levels.
Overall, the partnership between the Leander Paes-Samanta Sports Academy and the Glenmark Aquatic Foundation is a significant development for sports in Odisha, and is expected to have a lasting impact on the growth and development of tennis and swimming in the region. With the support of experienced professionals and world-class infrastructure, young athletes from Odisha will have the opportunity to pursue their dreams and achieve excellence in their chosen sports.
Zydus Lifesciences Hit with Rs 74.23 Crore GST Notice, to Contest the Ruling
Zydus Lifesciences, a prominent pharmaceutical company, is facing a significant demand of Rs 74.23 crore from the Goods and Services Tax (GST) authorities. The company plans to challenge this order, indicating a potential dispute over the tax assessment.
The GST demand on Zydus Lifesciences highlights the complexities and challenges that companies face in navigating the tax landscape in India. The pharmaceutical industry, in particular, has been subject to various regulatory and tax changes, which can impact their operations and financial performance.
Zydus Lifesciences is a leading player in the Indian pharmaceutical sector, known for its innovative products and research-driven approach. The company has a strong presence in the domestic market and exports its products to various countries worldwide.
The GST demand on Zydus Lifesciences is likely to be contested by the company, and the outcome of this dispute will be closely watched by the industry and tax experts. The company’s decision to challenge the order suggests that it believes the tax assessment is incorrect or unjustified.
The development comes at a time when the Indian government is actively working to simplify and streamline the tax system, including the GST regime. The government has introduced various measures to reduce compliance burdens and improve the overall business environment.
In this context, the dispute between Zydus Lifesciences and the GST authorities underscores the need for clarity and consistency in tax laws and regulations. The outcome of this case will have implications not only for the company but also for the broader pharmaceutical industry, which is a significant contributor to India’s economy.
As the case progresses, it will be interesting to see how the company and the tax authorities navigate the complex issues involved. The dispute highlights the importance of effective tax management and compliance for businesses operating in India, particularly in regulated sectors like pharmaceuticals.
Overall, the GST demand on Zydus Lifesciences is a significant development that will be closely monitored by the industry, tax experts, and regulatory authorities. The outcome of this dispute will have implications for the company, the pharmaceutical sector, and the broader business environment in India.
Cipla Limited Announces Acquisition of 100% Stake in Inzpera Healthsciences at ₹110.65 Crore – geneonline.com
Cipla Limited, a leading pharmaceutical company, has announced its plans to acquire a 100% stake in Inzpera Healthsciences Private Limited, a healthcare startup, for a consideration of ₹110.65 crore. This acquisition is expected to strengthen Cipla’s presence in the pharmaceutical market and expand its product offerings.
Inzpera Healthsciences is a specialty healthcare company that focuses on developing and commercializing innovative pharmaceutical products. The company has a strong portfolio of products in the areas of respiratory, dermatology, and oncology, among others. With this acquisition, Cipla will gain access to Inzpera’s product pipeline, which includes several branded and generic products.
The acquisition is expected to be completed within the next few months, subject to regulatory approvals. Cipla will pay ₹110.65 crore to acquire the entire stake in Inzpera Healthsciences, which includes the company’s assets, liabilities, and intellectual property. The acquisition will be funded through Cipla’s internal accruals and is expected to be accretive to the company’s earnings.
This acquisition is part of Cipla’s strategy to expand its presence in the pharmaceutical market and enhance its product offerings. The company has been focusing on developing its respiratory, dermatology, and oncology portfolios, and the acquisition of Inzpera Healthsciences is expected to strengthen its position in these areas. Cipla’s managing director and global chief executive officer, Umang Vohra, stated that the acquisition is a strategic fit for the company and will help it to expand its product offerings and strengthen its position in the market.
The acquisition of Inzpera Healthsciences is also expected to provide Cipla with access to new markets and distribution channels. Inzpera has a strong presence in the Indian market, and Cipla plans to leverage this presence to expand its own reach and distribution network. Additionally, Cipla will also gain access to Inzpera’s research and development capabilities, which will help the company to develop new products and technologies.
Overall, the acquisition of Inzpera Healthsciences by Cipla is expected to be a strategic move for the company, which will help it to expand its presence in the pharmaceutical market and enhance its product offerings. The acquisition is also expected to provide Cipla with access to new markets, distribution channels, and research and development capabilities, which will help the company to drive growth and innovation in the future.
Delhi High Court’s Decision in F. Hoffmann-La Roche Ag & Anr. v. Natco Pharma – Cyril Amarchand Mangaldas
The Delhi High Court recently delivered a significant judgment in the case of F. Hoffmann-La Roche Ag & Anr. vs. Natco Pharma, which has far-reaching implications for the pharmaceutical industry. The court’s ruling pertains to the interpretation of Section 107A of the Indian Patents Act, 1970, which deals with the compulsory licensing of patents.
The case involved a dispute between F. Hoffmann-La Roche Ag (Roche), a Swiss pharmaceutical company, and Natco Pharma, an Indian generic drug manufacturer. Roche held a patent for the drug Erlotinib, used to treat non-small cell lung cancer. Natco Pharma sought to manufacture and market a generic version of the drug, which led to a patent infringement suit filed by Roche.
The key issue before the court was whether Natco Pharma’s actions constituted an infringement of Roche’s patent, and if so, whether the Indian government could grant a compulsory license to Natco Pharma to manufacture and sell the generic version of the drug. The court ultimately ruled in favor of Natco Pharma, holding that the company’s actions did not infringe Roche’s patent.
The court’s decision was based on its interpretation of Section 107A of the Indian Patents Act, which allows for the grant of a compulsory license in certain circumstances, including when a patent is not worked in India or when the reasonable requirements of the public are not met. The court held that Roche’s patent was not being worked in India, as the company was not manufacturing the drug in the country, and that the reasonable requirements of the public were not being met, as the drug was not widely available or affordable.
The court’s ruling has significant implications for the pharmaceutical industry, as it sets a precedent for the grant of compulsory licenses in cases where patents are not being worked in India or where the reasonable requirements of the public are not being met. The decision is also seen as a victory for generic drug manufacturers, who can now seek compulsory licenses to manufacture and market generic versions of patented drugs, making them more accessible and affordable to the public.
The judgment highlights the importance of balancing the rights of patent holders with the need to ensure access to affordable medicines. The court’s decision demonstrates that the Indian judiciary is committed to upholding the principles of public interest and ensuring that patents are not used to stifle competition or limit access to essential medicines. Overall, the ruling is a significant development in the field of intellectual property law in India and is likely to have far-reaching consequences for the pharmaceutical industry.
Cipla appoints Achin Gupta as its new CEO, effective April 2026, in addition to his current role as Chief Operating Officer.
Indian pharmaceutical company Cipla Ltd has announced a change in its leadership, with current Chief Operating Officer (COO) Achin Gupta set to take over as the company’s next Chief Executive Officer (CEO) and Managing Director. Gupta will succeed Umang Vohra, who has decided not to seek re-appointment after completing his current term on March 31, 2026. The transition is part of a planned succession process developed by the company’s board, and Gupta’s appointment is subject to shareholder approval.
Gupta, who joined Cipla in 2021 and became COO in February 2025, will assume his new role on April 1, 2026, for a five-year term. As COO, he currently oversees the company’s commercial markets, active pharmaceutical ingredient, manufacturing, and supply chain operations. Gupta has a strong educational background, holding an MTech in Biochemical Engineering and Biotechnology from IIT Delhi and an MBA from IIM Ahmedabad.
Outgoing CEO Umang Vohra has been with Cipla since 2015, serving as Global Chief Financial & Strategy Officer before taking over as MD & CEO in 2016. Cipla’s chairman, Dr. Y K Hamied, thanked Vohra for his dedication and contributions to the company, wishing him success in his future endeavors. Dr. Hamied expressed confidence in Gupta’s ability to lead Cipla to its next phase of growth and progress.
Gupta has expressed his honor at being entrusted with the responsibility of leading Cipla, stating that he is committed to driving the company’s purpose of “Caring for Life” and combining business with a humanitarian approach. With Gupta at the helm, Cipla is expected to continue its focus on delivering high-quality, affordable medicines to patients worldwide. The company’s planned transition is seen as a positive move, ensuring continuity and stability in its leadership, and positioning Cipla for future success in the competitive pharmaceutical industry.
Apollo Cradle Organizes its 3rd Annual National Conference in 2025
The 3rd National Cradle Conference (NCC 2025) was recently held in New Delhi, India, on November 1st and 2nd, 2025. The two-day conference was organized by Apollo Cradle and Apollo Fertility, and it brought together the country’s most renowned experts in maternal, women, and child health, as well as reproductive medicine. The conference was inaugurated by Dr. Sangita Reddy, Joint Managing Director of Apollo Hospitals, and was attended by other senior members of the hospital group.
The theme of the conference was “Uniting Expertise in Pre-Conception, Maternity & Child Care in India,” and it served as a premier forum for advancing clinical excellence, research, and collaboration. Over the two days, the conference highlighted the latest scientific and technological advances in various specialties, including neonatology, pediatrics, obstetrics, fetal medicine, and allied specialties. The expert-led sessions provided practical insights into updated guidelines and treatment protocols, helping clinicians stay informed and up-to-date.
The conference also emphasized the importance of integrating next-generation innovations, such as robot-assisted procedures, AI-enabled diagnostics, and advancements in reproductive, genomic, and neonatal medicine, into clinical practices. Dr. Sangita Reddy noted that Apollo’s collaborative ethos is guided by the objective of continuously elevating the standards of patient care across the entire continuum, from reproduction and pre-conception to delivery and child care.
The NCC 2025 conference was not just an academic event, but an evolutionary episode in medical science, involving knowledge sharing on topics such as rising infertility issues, reducing infant mortality, improving neonatal outcomes, and inducing preventive healthcare behaviors. The conference reflects Apollo’s continued commitment to elevating clinical standards through collective learning and shared expertise, and reinforces Apollo Cradle and Fertility’s mission to deliver holistic, patient-centered care from conception to childhood and overall wellbeing of women.
The conference was attended by distinguished experts, including Dr. Anupam Sibal, Group Medical Director, Apollo Hospitals, and Dr. Anita Kaul, Fetal Medicine Expert, Apollo Cradle, among others. The event served as a pivotal forum for redefining and refining best practices in women’s and child health, and provided a platform for clinicians to stay informed, up-skilled, and adaptive. Overall, the 3rd National Cradle Conference was a significant event that highlighted the latest advances and innovations in maternal, women, and child health, and reinforced Apollo’s commitment to delivering world-class patient care.
Apollo doctor weighs in: High AQI – to run outdoors or stay in? A 2-step plan to breathe easy
As air quality levels continue to deteriorate in Indian cities, fitness enthusiasts are becoming increasingly concerned about the safety of exercising outdoors when the Air Quality Index (AQI) is poor. Dr. Sudhir Kumar, a senior neurologist at Apollo Hospitals in Hyderabad, recently shared his expertise on the matter, providing clear guidance on how to balance fitness with health safety during periods of high pollution.
When a follower asked if running outdoors for 30 minutes in an AQI of around 200 was better than staying indoors without exercise, Dr. Kumar broke down the pros and cons of both options. While outdoor running has undeniable benefits, including improved cardiovascular health, metabolism, and mental well-being, polluted air poses serious risks that can offset these gains. According to Dr. Kumar, the deep, rapid breathing associated with running increases inhaled air volume, pulling 10-20 times more pollutants deep into the lungs.
Exposure to particulate matter (PM₂.₅) and ozone during intense activity is linked to airway inflammation, oxidative stress, reduced lung function, elevated blood pressure, and a higher long-term risk of respiratory and heart diseases. For individuals with pre-existing conditions such as asthma, cardiac conditions, or stroke risk, this exposure can be particularly harmful. As a result, Dr. Kumar concluded that when AQI levels reach 200, the harms of pollutant inhalation outweigh the short-term exercise benefits.
In contrast, staying indoors offers some protection from air pollution, with indoor pollutant levels typically 50-70% lower when windows are closed. However, Dr. Kumar cautioned that long-term sedentary behavior can also harm health. For short durations of high pollution, avoiding outdoor exercise is the safer option. To mitigate this, Dr. Kumar suggested a two-step approach: switching to indoor workouts, such as treadmill running or yoga, with windows closed and an air purifier running, and resuming outdoor activities only when the AQI drops below 100, ideally under 50.
For those who must venture outside, Dr. Kumar advised doing so in the early morning, wearing an N95 mask, and avoiding high-traffic areas. By following these guidelines, individuals can prioritize their health and safety while still maintaining their fitness routines. As a trusted and reliable news source, it is essential to consider expert advice like Dr. Kumar’s when navigating the challenges of exercising in polluted environments. By being informed and taking necessary precautions, individuals can minimize their risk and stay healthy.
Cipla names Achin Gupta as new Managing Director and Global Chief Executive Officer, set to take office on April 1, 2026.
Cipla Limited, a leading pharmaceutical company, has announced the appointment of Achin Gupta as its new Managing Director and Global Chief Executive Officer (MD & GCEO), effective April 1, 2026. Gupta will succeed Umang Vohra, who has led the company since 2016. This transition is part of Cipla’s robust succession strategy, ensuring continuity and stability for the company’s future growth.
Achin Gupta has been with Cipla since 2021, serving as CEO of the One India Business and later as Global Chief Operating Officer (GCOO) since February 2025. During his tenure, he has driven exceptional growth and operational excellence, achieving market-leading profitability and expanding the company’s presence in chronic therapies and underserved geographies. Gupta has also strengthened Cipla’s position as a preferred innovation-led collaborator through strategic global partnerships.
As the new MD & GCEO, Gupta has expressed his commitment to driving sustainable growth, deepening the company’s impact across markets, and continuing to innovate with purpose. He is inspired by Cipla’s legacy of purpose-driven innovation and patient-centric care, and he has witnessed the passion and resilience of the company’s teams.
The leadership transition marks an important milestone in Cipla’s nearly nine-decade journey of advancing access to affordable, quality healthcare. The company is committed to innovation and patient care, and under Gupta’s leadership, it will build on its legacy and strengthen global partnerships. Cipla will continue to shape the future of healthcare through innovation and purpose, with a focus on driving growth, expanding its presence, and improving the lives of patients worldwide.
The transition is seen as a seamless one, with Gupta’s experience and leadership style well-suited to take the company forward. The company’s robust succession strategy has ensured that the transition is smooth, and the future of Cipla looks bright under Gupta’s leadership. With his vision and commitment, Cipla is poised to continue its journey of providing affordable and quality healthcare to patients around the world.
Next week, several major companies, including Airtel, LIC, SBI, M&M, Sun Pharma, and Titan, are set to release their Q2 earnings reports.
The Indian corporate sector has reported earnings in line with expectations for the September quarter, boosting market sentiment. Several prominent companies, including Indian Oil Corporation, Adani Green Energy, and Hindustan Petroleum Corporation Limited, have already announced their quarterly results. The Q2 earnings season is now entering a crucial phase, with many blue-chip and growth-oriented companies set to release their July-September quarter results.
This week, starting from November 3, will be action-packed, with several key companies announcing their earnings. On Monday, Bharti Airtel and Ambuja Cements will release their results, providing insights into telecom and infrastructure demand. Other companies, including Tata Consumer Products, Titan Company, and Power Grid Corporation, will also announce their earnings, focusing on consumption and utilities.
On Tuesday, State Bank of India, the country’s largest lender, will be in the spotlight, with investors closely watching its asset quality and credit growth trends. The Adani Group, including Adani Enterprises and Adani Ports, will also release their results, along with Mahindra & Mahindra and IndiGo.
The following days will see earnings from pharmaceutical and FMCG giants, including Sun Pharma, Aurobindo Pharma, Britannia Industries, and Grasim Industries. Life Insurance Corporation (LIC) will also release its results, which is expected to draw significant retail interest. Other key earnings include Apollo Hospitals, Lupin, and Godrej Properties.
The week will conclude on Friday, with a mixed bag of companies from various sectors, including Hindalco Industries, National Aluminium, Divi’s Laboratories, Trent, and Power Finance Corporation. Overall, the Q2 earnings season is expected to provide valuable insights into the performance of various sectors and companies, influencing market sentiment and investor decisions. As always, investors are advised to consult with a qualified financial advisor before making any investment decisions.
Apollo clinicians and faculty members have been recognized in Stanford’s 2025 global ranking as among the top 2% of scientists worldwide.
Twelve clinicians and researchers from the Apollo Hospitals Group have been recognized in Stanford University’s 2025 Global List of the Top 2% Scientists. This prestigious list, compiled by Stanford University in collaboration with Elsevier, identifies the top 2% of scientists worldwide based on standardized citation indicators across multiple disciplines. The inclusion of Apollo’s experts in this global ranking acknowledges their significant contributions to medical science and research excellence.
The recognition is a testament to Apollo Hospitals’ sustained focus on clinical research, innovation, and academic collaboration across its network of hospitals and institutions. The organization’s clinicians and faculty have been featured in the global ranking, highlighting their growing contribution to evidence-based medicine and scientific advancement.
Dr. Preetha Reddy, Executive Vice Chairperson of Apollo Hospitals Enterprise Ltd., expressed pride in the achievement, stating that the clinicians and researchers exemplify the organization’s belief that care and innovation go hand in hand. Dr. Anupam Sibal, Group Medical Director of Apollo Hospitals Group, emphasized the importance of academics and research in the organization’s mission statement, noting that 1047 papers were published by Apollo’s faculty in journals worldwide in 2024.
The twelve honored clinicians and researchers are from various specialties, including psychiatry, orthopedics, head and neck surgical oncology, pediatric nephrology, and palliative medicine. They are based in different Apollo Hospitals locations across India, including Kolkata, New Delhi, Navi Mumbai, and Chennai. The recognition of these experts demonstrates Apollo Hospitals’ strengthening role at the intersection of clinical practice, research, and education, which is central to the evolution of modern healthcare.
The achievement is a proud moment for Apollo Hospitals and Indian healthcare, showcasing the organization’s commitment to excellence in medical science and research. The recognition of its clinicians and researchers in the global ranking is expected to further strengthen Apollo Hospitals’ position as a leader in the healthcare industry, both in India and globally.
Zydus Lifesciences has been instructed to revise the post-marketing surveillance study for its Tofacitinib Extended-Release Tablets.
Zydus Lifesciences, a pharmaceutical company, has been instructed to revise a post-marketing surveillance (PMS) study for its Tofacitinib ER (extended-release) tablets. The company had submitted the study protocol to the regulatory authorities, but it appears that the submission did not meet the required standards.
Tofacitinib is a medication used to treat various inflammatory conditions, including rheumatoid arthritis, ulcerative colitis, and psoriatic arthritis. The extended-release formulation of the tablets allows for once-daily dosing, which can improve patient compliance. However, as with any new drug or formulation, regulatory authorities require thorough evaluation of its safety and efficacy in real-world settings through PMS studies.
The revision of the PMS study protocol is crucial for several reasons. Firstly, it ensures that the study design is robust enough to capture accurate and reliable data on the safety and efficacy of Tofacitinib ER tablets in a large and diverse patient population. Secondly, the revised protocol must address any concerns or gaps identified by the regulatory authorities, which could include issues related to patient selection, data collection methods, and analytical approaches.
The requirement for revision may also indicate that the initial protocol did not fully adhere to regulatory guidelines or did not provide sufficient detail on how the study would handle potential challenges, such as patient dropout rates or the management of adverse events. The regulatory authorities’ feedback is an essential part of the drug development and approval process, ensuring that pharmaceutical companies conduct rigorous and meaningful research to support the safe and effective use of their products.
In response to the regulatory feedback, Zydus Lifesciences will need to revise and resubmit the PMS study protocol. This process involves addressing the specific concerns and recommendations provided by the regulatory authorities, which could require adjustments to the study design, methodology, or even the inclusion and exclusion criteria for patients. Once the revised protocol is approved, the company can proceed with conducting the PMS study, which will provide critical insights into the real-world performance of Tofacitinib ER tablets.
The outcome of the PMS study will be significant, not only for Zydus Lifesciences but also for patients and healthcare providers. It will contribute valuable information to the body of evidence supporting the use of Tofacitinib ER tablets, helping to optimize treatment strategies and improve patient outcomes. Through this process, regulatory authorities ensure that pharmaceutical companies maintain high standards of research and drug development, ultimately protecting public health and advancing medical science.
Apollo enhances its stroke care services by launching 9 additional laboratories.
Apollo Hospitals has recently announced the expansion of its Advanced Stroke Network in Tamil Nadu, making it the largest of its kind in the state. The network is designed to provide swift diagnosis and treatment for stroke patients in Chennai through a protocol-driven system and nine newly established advanced labs. This initiative is particularly crucial given the rising incidence of stroke cases, especially among younger populations, with one in four individuals over 25 at risk.
The importance of timely intervention in stroke management cannot be overstated, as approximately 190,000 brain cells are lost every minute during an attack. The Apollo Hospitals’ network ensures high-quality, uniform care for both ischemic and hemorrhagic strokes across its hospitals in Chennai. This is achieved through the utilization of advanced imaging, AI-enhanced diagnostic tools, and multidisciplinary expertise.
The expansion of the stroke network builds upon the hospital’s initial launch in 2023 and is aimed at improving early detection, survival, and recovery rates in the city. The network comprises top neurology and neurovascular specialists, including Dr. Srinivasan Paramasivam, who are dedicated to offering neuroendovascular treatments such as mechanical thrombectomy and microsurgical interventions. These treatments are critical in saving lives and enhancing patient outcomes.
India faces a significant challenge with approximately 13 million strokes occurring annually, and Chennai alone reports around 10,000 cases each year. The expansion of the Advanced Stroke Network by Apollo Hospitals is aligned with global efforts to address this growing health concern. By focusing on innovative and fast-track stroke care, the hospital aims to make stroke management more accessible and efficient, ultimately improving patient outcomes and saving lives. The continued expansion of this network underscores the hospital’s commitment to providing high-quality care and addressing the pressing health challenges faced by the community.
Medical experts sound alarm over increasing incidence of strokes in young people
On World Stroke Day, neurologists in Bengaluru sounded the alarm over the rising number of stroke cases among younger adults in India. This trend is concerning, as stroke was once primarily seen in older individuals. Experts attribute this shift to the adoption of unhealthy lifestyles, including poor sleep habits, stress, smoking, alcohol consumption, and physical inactivity. Dr. P Satishchandra, a senior consultant at Apollo Hospitals, emphasized that stroke has become a leading cause of death and disability in India, with a growing incidence among working-age adults due to uncontrolled hypertension, diabetes, and sedentary lifestyles.
The symptoms of stroke are often overlooked, leading to delays in seeking treatment, which can be dangerous. Dr. Lokesh B, a consultant at Aster CMI Hospital, noted that millennials and Gen Z are increasingly vulnerable to stroke due to digital stress, erratic sleep patterns, long work hours, and poor lifestyle choices. Many young adults mistake early signs of stroke, such as dizziness, slurred speech, or numbness, for tiredness or anxiety, rather than seeking medical attention.
In addition to well-known risk factors, doctors are highlighting the importance of addressing lesser-known contributors to stroke, such as sleep apnea. Dr. Avinash Kulkarni, a consultant neurologist at Gleneagles BGS Hospital, explained that sleep-disordered breathing can cause surges in blood pressure and inflammation, weakening cerebral vessels and increasing the risk of stroke. He noted that many patients with controlled diabetes or hypertension still suffer from recurrent strokes due to undiagnosed Obstructive Sleep Apnea (OSA).
Overall, the growing incidence of stroke among younger adults in India is a worrying trend that requires attention and action. By raising awareness about the risks and symptoms of stroke, and promoting healthy lifestyle choices, individuals can reduce their risk of stroke and improve their overall health. It is essential to prioritize sleep, exercise, and stress management, and to seek medical attention immediately if symptoms of stroke occur. By taking these steps, we can work towards reducing the burden of stroke in India and promoting a healthier future for all.
Cipla Health ventures into sexual wellness sector with introduction of Unfold brand
Cipla Health, a leading consumer healthcare company in India, has launched a new brand called Unfold, which marks its entry into the sexual wellness category. Unfold aims to promote openness, trust, and choice in intimate wellbeing, and its visual identity was developed in collaboration with dCell, the design arm of MullenLowe Lintas Group. The goal was to create a modern and distinctive look that would set a fresh tone for the category and stand out among global condom labels.
According to Shivam Puri, Managing Director and CEO of Cipla Health, the company is committed to providing wellness products that enhance overall health and wellbeing. With Unfold, the company has entered the sexual wellness category with products guided by strong consumer insights, where trust is a paramount consumer need. The packaging design plays a crucial role in establishing brand credentials, and dCell has translated these insights into a modern packaging design that feels fresh and reframes intimacy while staying stigma-free.
The design of Unfold’s logo and packaging is inspired by the idea of “unfolding” layers of passion and intimacy. The bold, vibrant colors and dynamic design system evoke excitement and desire, while a metallic holographic finish adds a layered, premium appeal. Bhumika Shah, Executive Design Director at dCell, notes that Unfold is more than just a product – it’s a step towards normalizing conversations around intimacy in India. The brand’s stylish, modern, and aspirational identity reflects a growing demand for sexual wellness products that are discreet, aesthetically appealing, and uncompromising on quality.
The response to Unfold has been encouraging, with both consumers and trade partners showing positive feedback. The brand is on its journey to deliver real impact and promote a more open and stigma-free conversation around intimacy in India. With Unfold, Cipla Health aims to provide a fresh perspective on the sexual wellness category and establish itself as a leader in the market. The brand’s modern and distinctive design is expected to appeal to a new generation of consumers who are looking for products that are both effective and aesthetically pleasing.
Cipla Health and MullenLowe’s dCell launch new brand focused on sexual wellness
Cipla Health, a leading healthcare company, has launched a new brand called Unfold, marking its entry into the sexual wellness segment. The brand’s design and visual identity were developed by dCell, a design agency, to redefine how intimacy is represented in India’s healthcare market. Unfold’s packaging features a modern and minimal aesthetic, positioning the brand alongside global names in the sexual wellness space while resonating with Indian consumers.
According to Shivam Puri, Managing Director and CEO of Cipla Health, the launch of Unfold is a significant step towards providing wellness products that focus on enhancing overall health and wellbeing. The company conducted extensive consumer research to understand the needs and preferences of Indian consumers, and the findings guided the development of Unfold’s product offerings. Puri emphasized that trust is a paramount consumer need in the sexual wellness category, and packaging plays a crucial role in establishing brand credentials.
The packaging design of Unfold was created to be fresh, modern, and stigma-free. The design features bold, vibrant colors and a dynamic system that evokes excitement and desire. A metallic holographic finish adds a premium appeal to the packaging. Bhumika Shah, Executive Design Director at dCell, explained that Unfold is more than just a product – it’s a step towards normalizing conversations around intimacy in India. The brand’s design reflects a growing demand for sexual wellness products that are discreet, aesthetically appealing, and uncompromising on quality.
With the launch of Unfold, Cipla Health expands its wellness portfolio and addresses evolving consumer attitudes towards intimacy and self-care. The brand’s design-forward approach bridges functionality and emotion, offering a unique and refreshing perspective on the sexual wellness category. The response from consumers and trade partners has been encouraging, and Unfold is poised to make a significant impact in the market. Overall, Unfold represents a significant step forward in promoting healthy and open conversations about intimacy and sexual wellness in India.
Cipla Enters India’s Weight-Loss Segment with ‘Yurpeak’, a Repurposed Version of Mounjaro
India’s weight-loss market has welcomed a new player with the launch of ‘Yurpeak’ by Cipla, a popular pharmaceutical company. Yurpeak is the brand name given to the medication Mounjaro, which has been approved by the US FDA for the treatment of type 2 diabetes. However, its effectiveness in weight loss has also been widely recognized. With the introduction of Yurpeak, Cipla aims to tap into the growing demand for weight-loss solutions in India.
Mounjaro, the original medication, is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood sugar levels and promotes weight loss. Clinical trials have shown that Mounjaro can lead to significant weight loss, with some patients losing up to 15-20% of their body weight. This has generated significant interest in the medication as a potential treatment option for obesity.
Cipla’s entry into the weight-loss market with Yurpeak is strategic, given the increasing prevalence of obesity and related health issues in India. The country is home to a large population struggling with weight-related problems, and the market for weight-loss solutions is expected to grow significantly in the coming years. By launching Yurpeak, Cipla is poised to capitalize on this trend and establish itself as a major player in the Indian weight-loss market.
The launch of Yurpeak is also expected to increase awareness about the importance of weight management and the availability of effective treatment options. Cipla plans to promote Yurpeak through a targeted marketing campaign, highlighting its benefits and effectiveness in weight loss. The company will also engage with healthcare professionals to educate them about the medication and its potential to address the growing obesity epidemic in India.
While the launch of Yurpeak is a significant development in India’s weight-loss market, it is essential to note that the medication should only be used under medical supervision. As with any prescription medication, there may be potential side effects and risks associated with Yurpeak, and patients should consult their healthcare provider before starting treatment.
In conclusion, the launch of Yurpeak by Cipla marks a new era in India’s weight-loss market. With its proven effectiveness in weight loss and Cipla’s strong presence in the Indian pharmaceutical market, Yurpeak is expected to make a significant impact on the country’s obesity landscape. As the demand for weight-loss solutions continues to grow, Cipla is well-positioned to capitalize on this trend and establish itself as a leader in the Indian weight-loss market.
DK Shivakumar, DCM, holds meeting with industry leaders to address Bengaluru’s infrastructure concerns
In a bid to address the concerns of industrialists over Bengaluru’s poor infrastructure, Deputy Chief Minister DK Shivakumar held a meeting with prominent business leaders, including Biocon founder Kiran Mazumdar-Shaw and former Infosys CFO Mohandas Pai. The meeting, which took place over dinner on Saturday, aimed to discuss the city’s key infrastructure bottlenecks, including potholes, traffic, and garbage management. The gathering was also attended by Greater Bengaluru Authority Chief Commissioner M Maheshwar Rao, Bengaluru Business Corridor Chairman LK Atheeq, and former JDS spokesperson Tanveer Ahmed, among others.
The meeting was a response to recent criticism from Kiran and Pai, who had expressed their frustration over the city’s infrastructure issues. Their comments had sparked a backlash from Congress ministers, who suggested that they should use their corporate social responsibility (CSR) funds to contribute to the city’s development. However, the tone of the meeting was constructive, with Kiran Mazumdar-Shaw describing it as a positive discussion on an action plan to address the city’s key infrastructure challenges.
Shivakumar acknowledged that the criticism from industrialists had gained international attention, and emphasized the need to work together to find solutions. He appreciated the suggestions offered by the business leaders and announced that they would be included in the main advisory committee to contribute to the city’s development. The Deputy Chief Minister recognized that the challenge lies in working through the bureaucratic framework, which can be time-consuming due to the need to follow legal protocols.
The meeting marks a significant step towards collaboration between the government and the business community in addressing Bengaluru’s infrastructure woes. By engaging with prominent industrialists and incorporating their suggestions, the government aims to find effective solutions to the city’s problems and improve its overall development. The inclusion of business leaders in the advisory committee is expected to bring in fresh perspectives and expertise, ultimately contributing to the betterment of Bengaluru’s infrastructure.
Biography, Family Background, Professional Journey, Wealth, and Other Interesting Facts
Upasana Kamineni Konidela is a renowned businesswoman, philanthropist, and spouse of South Indian superstar Ram Charan Teja. Born on July 20, 1989, in Hyderabad, she hails from one of India’s most influential families. Her great-grandfather, Dr. Prathap C. Reddy, founded Apollo Hospitals, a leading hospital chain in India. Upasana’s parents, Anil Kamineni and Shobana Kamineni, are also prominent figures in their respective business sectors.
Upasana graduated from Regent’s University in London with a degree in business and marketing. She began her career in the hospital industry and is currently the Vice Chairperson of Apollo Life. She is also the Editor-in-Chief of B Positive Magazine, advocating for holistic health, sustainability, and mental wellness. Through the Apollo Foundation, she provides medical aid and awareness to marginalized communities, contributing significantly to corporate wellness and employee productivity in India.
Upasana’s philanthropic efforts have earned her the Dadasaheb Phalke Award for Benefactor of the Year. She married Ram Charan Teja in 2012, and the couple has a daughter, Klin Kaara Konidela, born in June 2023. Upasana’s estimated net worth is between $100 million, derived from her stake in Apollo Hospitals, business leadership roles, and investments.
Apart from her professional achievements, Upasana is known for her innate beauty and sophisticated fashion sense. She stands at 173 cm, weighs around 55 kg, and has dark brown hair and brown eyes. As a mother, she has been showered with congratulations from fans and well-wishers on social media, marking a new era for the Konidela family. Upasana’s family includes her father, Anil Kamineni; mother, Shobana Kamineni; brother, Puansh Kamineni; and husband, Ram Charan Teja. Her sisters-in-law are Sushmita Konidela and Sreeja Kalyan.
Upasana’s commitment to wellness, sustainability, and social entrepreneurship has made her a respected figure in India. Her leadership roles in Apollo Life and the Apollo Foundation demonstrate her dedication to improving healthcare and community welfare. As a member of one of India’s most influential families, Upasana has carved out her own path, making a significant impact in the fields of healthcare, wellness, and social entrepreneurship.
Glenmark Pharmaceuticals Inc., USA will introduce Ropivacaine Hydrochloride Injection USP in three concentrations: 2mg/mL, 5mg/mL, and 10mg/mL, available in 20mL and 30mL single-dose vials.
Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of Ropivacaine Hydrochloride Injection USP, a generic version of Naropin Injection, in November 2025. The new product will be available in three strengths: 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials. According to IQVIA sales data, the Naropin Injection market achieved annual sales of approximately $20.9 million for the 12-month period ending August 2025.
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to Naropin Injection, making it a quality and affordable alternative for patients. The launch of this product represents another important addition to Glenmark’s expanding injectable portfolio, reinforcing the company’s dedication to providing quality and affordable alternatives to market for patients in need.
Marc Kikuchi, President & Business Head, North America, commented on the launch, stating that the company is pleased to announce the launch of Ropivacaine Hydrochloride Injection USP. Glenmark’s product is only approved for the indications listed in the company’s approved label, which may not include all the indications for the reference listed drug, Naropin Injection.
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company with a presence across Branded, Generics, and OTC segments, focusing on therapeutic areas such as respiratory, dermatology, and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark has been recognized as one of the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023 and one of the Top 50 Generics and biosimilar companies ranked by sales in 2024.
The company has also made a commitment to reduce its Green House Gas (GHG) emission, with targets approved by the Science Based Target initiative (SBTi) in 2023. Glenmark’s CSR interventions have impacted over 3.3 million lives over the last decade. The company can be found on LinkedIn and Instagram, and more information is available on their website, www.glenmarkpharma.com.
Health Canada grants approval for BBL’s Yesintek and Yesintek I.V. products.
Biocon Biologics Ltd, a global biosimilars company, has announced that Health Canada has granted approval for Yesintek, a biosimilar to Stelara, for the treatment of several moderate to severe autoimmune diseases. The approval includes both subcutaneous and intravenous formulations of the drug, which will be available in Canada by mid-October. Yesintek has been shown to be highly similar to Stelara, with no clinically meaningful differences in efficacy, safety, or immunogenicity.
The approval is a significant step in Biocon Biologics’ mission to expand access to advanced biologic therapies across North America. Yesintek will be used to treat conditions such as plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis, which affect thousands of Canadians. The arrival of an affordable biosimilar option is a welcome development for patients and healthcare providers alike.
The approval of Yesintek is based on a comprehensive data package that demonstrates its similarity to Stelara. The drug will be made available through the My Biocon Biologics Patient Support Program, which provides tailored assistance to patients prescribed the therapy. The program ensures smooth access and ongoing support for patients.
The available formulations of Yesintek include a subcutaneous injection and an intravenous solution. The approval strengthens Biocon Biologics’ global footprint and enhances its immunology portfolio with a more affordable treatment option for Canadian patients. The company remains committed to advancing biosimilar adoption in Canada to improve patient outcomes and deliver meaningful savings to the healthcare system.
With this approval, Biocon Biologics continues to reinforce its leadership in biosimilar innovation and accessibility. The launch of Yesintek in Canada adds to the company’s expanding global footprint and underscores its commitment to making advanced biologic treatments more affordable and widely available. This is a crucial step toward improving patients’ quality of life worldwide. Biocon Biologics’ CEO and Managing Director, Shreehas Tambe, stated that the approval marks a significant milestone in the company’s mission to expand global access to high-quality biosimilars.
ABRYSVO Secures Enhanced Public Funding in Multiple Canadian Provinces for the 2025-2026 Respiratory Syncytial Virus Season
Pfizer Canada has announced that its vaccine, ABRYSVO, for the prevention of Respiratory Syncytial Virus (RSV), will be publicly funded in multiple provinces and territories across Canada for the 2025-2026 season. This decision reflects the growing recognition of the burden RSV places on older adults and the importance of proactive immunization strategies. Following a successful national tender process, ABRYSVO will be offered as a publicly funded option in several provinces, with expanded eligibility criteria that align with the latest recommendations from the National Advisory Committee on Immunization (NACI).
The expansion of public funding for RSV immunization is a significant step in prioritizing RSV prevention and ensuring that vulnerable populations have access to immunization options. Ontario will continue to offer RSV immunization for pregnant individuals and will expand the program to older adults, offering ABRYSVO as an option to help protect infants from birth through their first months of life.
RSV is often misunderstood or overlooked, but it can have devastating consequences, particularly for older adults and young children. Laura Tamblyn Watts, CEO of CanAge, welcomed the expansion of public funding for RSV immunization, stating that every step taken to protect vulnerable populations helps reduce hospitalizations and improves quality of life.
ABRYSVO is the first and only RSV vaccine indicated for adults 18 years and older, and it also has a dual indication to help protect adults and infants from birth to 6 months of age through maternal immunization. This addresses a substantial unmet need and provides a valuable tool in the prevention of RSV.
Individuals who are not covered by the public program may still have access to ABRYSVO through private coverage. Pfizer Canada will provide additional information regarding provincial implementation and eligibility requirements as updates are released. The company is committed to setting the standard for quality, safety, and value in the discovery, development, and manufacture of healthcare products, and this announcement reflects its ongoing efforts to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time.
Ram Charan and wife Upasana Kamineni are expecting their second child, heralding a new addition to the family that controls the vast Apollo Hospitals empire worth Rs 77,000 crore.
Ram Charan and Upasana Kamineni, a prominent celebrity couple in India, have announced that they are expecting their second child. The news was shared on social media through a heartwarming Diwali video, which featured the couple and their first child, a girl born in June 2023. The video concluded with the phrase “New beginnings,” leaving fans overjoyed and eager to congratulate the couple. Ram Charan captioned the post, “This Diwali was all about double the celebration, double the love and double the blessings,” which sparked a frenzy of love and well-wishes from fans and the film fraternity.
Upasana Kamineni, a billionaire heiress to the Apollo Hospitals’ Rs 77,000 crore business, is a formidable presence in her own right. She serves as the Vice Chairperson of the Apollo Foundation and the Managing Director of Family Health Plan Insurance TPA Limited. She has also established a wellness platform called UR.Life, which focuses on holistic health. As the granddaughter of Dr. Prathap C. Reddy, the founder of Apollo Hospitals, Upasana hails from a esteemed business lineage.
The couple’s personal life is a testament to their opulent lifestyle. They reside in a 25,000-square-foot home in Hyderabad, worth Rs 30 crore, which features tranquil gardens, selected artwork, and a wellness area crafted by Upasana. Their collection of vehicles includes a Rolls Royce Phantom and a Ferrari Portofino, and they also own a private jet.
Ram Charan and Upasana’s total net worth is estimated to exceed Rs 2,500 crore, making them one of India’s wealthiest and most powerful celebrity pairs. As they prepare to welcome their second child, it is clear that their life is set to become even more lively. With Ram Charan’s continued success in the film industry and Upasana’s advocacy for mental health, wellness, and women’s leadership initiatives, the couple embodies a unique blend of allure, aspiration, and practicality. As they embark on this new chapter in their life, they are surrounded by love, laughter, and light, and their fans wish them all the best for the future.
NATCO Pharma Limited’s ability to maintain steady cash flow during economic downturns is being reassessed.
NATCO Pharma Limited is an Indian pharmaceutical company that has been facing challenges in maintaining stable cash flow during market downturns. According to recent statistics, the company’s cash flow has been volatile, with significant fluctuations in its operating cash flow and free cash flow. This volatility has raised concerns among investors and analysts, who are questioning the company’s ability to deliver stable cash flow in the face of market uncertainty.
One of the key challenges facing NATCO Pharma is the intense competition in the pharmaceutical industry, which has led to pricing pressure and margin erosion. The company’s revenue has been impacted by the decline in prices of certain key products, which has resulted in a decrease in operating cash flow. Additionally, the company’s high dependence on a few key products has made it vulnerable to market fluctuations, which can impact its cash flow.
Despite these challenges, NATCO Pharma has been taking steps to diversify its product portfolio and reduce its dependence on a few key products. The company has been investing in research and development, which has led to the launch of new products and the expansion of its existing product lines. This diversification is expected to help the company reduce its volatility and improve its cash flow stability.
Another factor that is expected to contribute to NATCO Pharma’s cash flow stability is the growing demand for pharmaceuticals in emerging markets. The company has a strong presence in countries such as India, Brazil, and Russia, which are expected to drive growth in the pharmaceutical industry. As the demand for pharmaceuticals increases in these markets, NATCO Pharma is well-positioned to benefit from this trend and improve its cash flow.
In conclusion, while NATCO Pharma Limited has faced challenges in maintaining stable cash flow during market downturns, the company is taking steps to address these challenges. Through diversification of its product portfolio and expansion into emerging markets, NATCO Pharma is expected to improve its cash flow stability and deliver stable cash flow to its investors. However, the company’s ability to execute on its strategy and navigate the challenges of the pharmaceutical industry will be critical to its success. As the market continues to evolve, it will be important for investors and analysts to monitor NATCO Pharma’s progress and adjust their expectations accordingly. With a strong product pipeline and a growing presence in emerging markets, NATCO Pharma is well-positioned to deliver stable cash flow and drive growth in the pharmaceutical industry.
Donald Trump’s proposed plan to lower prescription drug costs is still uncertain and has not been finalized for pharmaceutical companies.
The Trump administration’s plan to lower drug prices, announced in May, is not a guaranteed success for pharmaceutical companies. Despite the plan’s relatively mild measures, which have been well-received by the industry, there are several reasons why it may not achieve its intended goals.
One major reason is that the plan relies heavily on voluntary actions from pharmaceutical companies, which may not be willing to comply. The plan encourages companies to re-import drugs from other countries, where prices are generally lower, but this would require them to absorb significant losses. Additionally, the plan proposes to ban gag clauses that prevent pharmacists from informing patients about cheaper alternatives, but this would require companies to surrender some of their control over the supply chain.
Another reason is that the plan does not address the underlying drivers of high drug prices, such as the lack of transparency in pricing and the limited competition in the market. The plan does not include any measures to increase transparency or promote competition, which means that companies may continue to charge high prices for their products.
Furthermore, the plan faces significant opposition from Democrats and some Republicans, who argue that it does not go far enough to address the issue of high drug prices. Many lawmakers are pushing for more drastic measures, such as allowing Medicare to negotiate prices directly with pharmaceutical companies or importing drugs from other countries. If these lawmakers are successful, the plan could be significantly altered or even replaced.
The pharmaceutical industry is also facing growing public pressure to lower prices, which could lead to increased scrutiny and regulation. Patients and advocacy groups are becoming increasingly vocal about the high cost of prescription drugs, and some companies are already facing lawsuits and congressional investigations over their pricing practices.
In conclusion, while the Trump administration’s plan to lower drug prices may have been well-received by pharmaceutical companies, it is not a done deal. The plan’s reliance on voluntary actions, lack of measures to address underlying drivers of high prices, and opposition from lawmakers and the public all pose significant challenges to its success. As a result, pharmaceutical companies should not assume that the plan will shield them from further scrutiny and regulation. Instead, they should be prepared to adapt to a changing landscape and potentially significant reforms in the coming years.
Piramal i-Know introduces the #OwnYourMenopause initiative to educate and inform about the signs and symptoms associated with menopause.
On World Menopause Day, i-Know, a women’s health brand from Piramal Pharma, launched a campaign called #OwnYourMenopause. The campaign aims to address the often-overlooked topic of menopause and its symptoms, which can be confusing and difficult to articulate. The goal is to help women find the words to describe their experiences, encourage open conversations, and empower them to take control of this natural life transition.
The campaign uses metaphor-led storytelling to translate the indescribable symptoms of menopause, such as brain fog and hot flashes, into relatable and emotional stories. These stories offer a sense of community and remind viewers that they are not alone and that help exists. The campaign also highlights i-Know’s Menopause Testing Kit, a home-based urine test that detects elevated Follicle Stimulating Hormone (FSH) levels, a key indicator of menopause onset.
According to Abhishek Kumar Srivastava, VP Marketing at Piramal Consumer Healthcare, the campaign reflects the company’s commitment to driving education and access, making it easier for women to identify what they’re going through and take timely, informed action. Mahima Mathur, Creative Director at DDB Mudra Group, added that the campaign aims to make it easier for women to talk, understand, and turn a lonely journey into a shared one.
The #OwnYourMenopause campaign is part of i-Know’s mission to empower women through awareness, from fertility to menopause and beyond. The campaign serves as a reminder that knowledge is the first step toward ownership, and that every phase of womanhood deserves to be understood, supported, and celebrated. By launching this campaign, i-Know hopes to normalize the conversation around menopause and provide women with the tools and resources they need to take control of their health.
The campaign is the result of a collaborative effort between i-Know and DDB Mudra Group, with a team of creatives, strategists, and business leaders working together to bring the concept to life. The campaign includes a series of films that showcase real stories of women navigating perimenopause and menopause, and is supported by the i-Know Menopause Testing Kit, which is designed to simplify early detection and empower women with greater awareness and control over their health.
The sector is experiencing a transitional quarter, hindered by declining gRevlimid sales and the weight of GST impact on overall growth.
The pharmaceutical sector is expected to experience a soft quarter in Q2FY26, according to brokerages. This period is seen as a transition phase for the industry, with both positive and negative factors at play. On the positive side, several companies have shown promising developments. Lupin, for instance, is expected to benefit from its US launches, which should contribute to its growth. Divi’s, on the other hand, has seen strong traction in its Contract Development and Manufacturing Organization (CDMO) business, which is a promising area for the company. Additionally, Sun Pharmaceuticals and Torrent Pharmaceuticals are expected to post resilient growth in the Indian market, driven by their strong product portfolios and distribution networks.
However, there are also several concerns that are weighing on the sector. One of the key worries is the erosion of sales of Revlimid, a key drug for several pharmaceutical companies. This is expected to have a negative impact on the companies’ top lines. Another concern is the impact of the Goods and Services Tax (GST) on the sector, which has led to destocking in the trade channel. This is expected to affect the sales of pharmaceutical companies in the short term. Furthermore, pricing pressure remains a concern for the sector, as governments and regulatory bodies continue to push for lower prices. Finally, there are also risks related to US tariffs, which could affect the exports of Indian pharmaceutical companies to the US.
Overall, the Q2FY26 quarter is expected to be a challenging one for the pharmaceutical sector, with both positive and negative factors at play. While some companies are expected to benefit from their US launches, CDMO traction, and resilient India growth, others will be impacted by the erosion of key drug sales, GST-led destocking, pricing pressure, and US tariff risks. Brokerages are advising investors to be cautious and selective in their investments in the sector, focusing on companies with strong product portfolios, robust distribution networks, and a proven track record of navigating regulatory challenges. By doing so, investors can navigate the challenges of the transition phase and position themselves for potential growth in the long term.
Kiran Mazumdar-Shaw Stands Firm On Kannada Pride Despite Fierce Criticism Over Bengaluru’s Infrastructure Remarks
Kiran Mazumdar-Shaw, the founder of Biocon, has defended her identity as a Kannadiga after facing backlash for her comments on Bengaluru’s infrastructure. In a recent post, she reaffirmed her love for the city and the Kannada culture, stating that she has spent seven decades living in the city and is proud to be a Kannadiga. Mazumdar-Shaw’s comments come after she criticized the poor roads and garbage management in Bengaluru, which drew sharp criticism from Karnataka officials and pro-Kannada activists.
The criticism was not only limited to her comments on infrastructure but also questioned her loyalty to Karnataka. Some netizens cited her opposition to policies favoring locals, such as the Karnataka Job Quota Bill, and her stance in the Cauvery water dispute. Additionally, her resistance to renaming Bangalore to Bengaluru was also brought up. However, others defended Mazumdar-Shaw, highlighting her decades-long contributions to Bengaluru’s growth and development.
As the founder of Biocon, Mazumdar-Shaw has played a significant role in establishing the city as a global biotech hub, creating thousands of jobs and putting the city on the map. Her defenders argued that her professional and personal connection to the city should outweigh any political or cultural criticisms. Deputy Chief Minister DK Shivakumar was among those who criticized Mazumdar-Shaw’s comments, but her supporters countered that her legacy and contributions to the city should be taken into account.
Mazumdar-Shaw’s post was a clear response to the criticism, as she stated, “I don’t think I am answerable to anyone who questions my loyalty to Karnataka.” Her statement reflects her confidence in her identity as a Kannadiga and her commitment to the city and its culture. The debate surrounding Mazumdar-Shaw’s comments highlights the complex issues surrounding identity, culture, and loyalty in the context of Bengaluru and Karnataka. While some may question her loyalty, others see her as a proud Kannadiga who has made significant contributions to the city’s growth and development.
Pfizer’s Accord for a Healthier World initiative is redefining traditional stability study protocols.
Pfizer’s Accord for a Healthier World program is a comprehensive initiative aimed at addressing healthcare disparities by providing the company’s full portfolio of medicines and vaccines on a not-for-profit basis to 45 lower-income countries. However, many of these countries are located near the equator with extreme tropical climates, posing a challenge for the stability testing of medicines and vaccines. The International Council for Harmonisation (ICH) has designated five stability zones, with Zone IVa and Zone IVb presenting the greatest challenges due to high heat and humidity conditions.
Pfizer’s scientists have developed a novel statistical approach to estimate shelf life in Zone IV markets without the need for new long-term studies. This approach leverages existing long-term data from Zone II conditions and short-term accelerated data to provide a scientifically sound estimation of shelf life. The World Health Organization’s (WHO) stability guidance allows for alternative approaches if they are scientifically justified, providing flexibility for initiatives like the Accord.
The approach uses the Arrhenius model to interpolate the expiry at Zone IV conditions, taking into consideration all stability-limiting attributes for each product and the probability of breaching specified limits. The model has been applied to two product examples, which will be presented at the International Society for Pharmaceutical Engineering’s 2025 ISPE Annual Meeting & Expo.
The development of this novel approach is crucial for increasing access to quality medicines and vaccines in lower-income countries. By estimating shelf life in Zone IV markets, Pfizer can ensure that its products are safe and effective for use in these regions. The company hopes to engage with regulatory agencies and receive feedback from peers to further validate the model.
The ultimate goal is to apply this model more broadly, beyond Pfizer’s portfolio, to save on sample and testing resources. This could have a significant impact on global health equity, as many lower-income countries struggle to access quality medicines and vaccines due to lack of stability testing. By sharing this approach, Pfizer aims to contribute to the development of more effective and sustainable healthcare systems in these regions.
The Accord for a Healthier World program is a significant step towards addressing healthcare disparities, and the development of this novel statistical approach is a crucial component of this initiative. By providing access to quality medicines and vaccines, Pfizer is helping to close the health equity gap and ensure that people in lower-income countries have access to the same level of healthcare as those in higher-income countries.
The Supreme Court has issued a notice to Fortis Hospital and other parties in response to a petition seeking compensation for a brain injury.
The Supreme Court of India has issued a notice to Fortis Hospital in response to a plea filed by an 8-year-old child, Devarsh Jain, seeking compensation of Rs 1350 crore for an alleged brain injury at birth in 2017. The child, who is in a vegetative state, approached the court through his mother, alleging that two pediatricians employed by the hospital caused him severe brain damage due to their reckless handling. The damage has resulted in the child suffering from cerebral palsy, epilepsy, and severe visual impairment, leaving him mute and unresponsive.
The appeal was filed against the National Consumer Dispute Redressal Commission (NCDRC), which dismissed the original complaint in March 2025. The NCDRC’s decision was challenged by the child’s mother, who argued that the commission had misconstrued the facts of the complaint and treated it as a public interest litigation against the entire medical industry. The Supreme Court has listed the matter for further hearing on December 8, 2025.
The child’s lawyers, senior advocate Menaka Guruswamy and advocate Rajiv Ranjan Dwivedi, argued that the two pediatricians responsible for the child’s care were unqualified and had been appointed to senior positions in the hospital’s Neonatal Intensive Care Unit (NICU). They alleged that the doctors’ mishandling of the child had caused irreversible brain damage, resulting in a permanent vegetative state.
Fortis Hospital has responded to the allegations, stating that it has not yet been served with a notice from the Supreme Court and will review the allegations and issue a formal response once the relevant documents and legal filings are received. The hospital has retained its rights to review the allegations and will respond in accordance with the law.
The case highlights the issue of medical negligence and the need for accountability in the healthcare sector. The Supreme Court’s decision to issue a notice to Fortis Hospital is a significant development in the case, and the outcome of the hearing on December 8, 2025, will be closely watched. The child’s family is seeking compensation for the alleged negligence, which they claim has resulted in a lifetime of suffering and disability for the child.